Oncology & Cancer

Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer

Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than the same targeted therapy ...

Oncology & Cancer

The secret DNA circles fueling pancreatic cancer's aggression

Pancreatic cancer is one of the deadliest cancers worldwide, with a five-year survival rate of 13%. This poor prognosis stems from both late detection and the cancer's notorious capacity to adapt and resist therapy.

page 2 from 40